Adjuvant Therapies or Surgery Alone for High Risk pN0 Esophageal Cancer
Status:
Unknown status
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
Histological Node Negative thoracic esophageal squamous cell carcinoma（pN0 ESCC） after
radical resection still carries the risk of recurrence after complete surgical resection,
especially in some high-risk patients. There are still lack of knowledge on postoperative
treatment indication and methods for pN0 ESCC.Our previous study has shown that risk of
recurrence is associated with the location and cell differentiation of primary tumor, as well
as the presence of lymphovascular invasion. This project is designed to study the efficacy of
adjuvant therapies for at patients with pN0 ESCC and above mentioned risk factors of
recurrence after radical surgery. We aim to compare the differences among adjuvant
chemotherapy, adjuvant radiotherapy, and surgery alone for pN0 ESCC by prospective randomized
controlled trial. There has been no similar studies in esophageal cancer previously reported
with similar design. The results of this study is expected to have a high clinical relevance.
Phase:
Phase 3
Details
Lead Sponsor:
Shanghai Chest Hospital
Collaborators:
Fudan University Fujian Cancer Hospital Fujian Medical University Hunan Cancer Hospital Qingdao University Sichuan Cancer Hospital and Research Institute Sun Yat-sen University Tianjin Medical University Cancer Institute and Hospital Wuhan TongJi Hospital